Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacira Pharmaceuticals reports record revenues and optimistic growth outlook

Pacira Pharmaceuticals had a strong financial performance in 2022, driven by EXPAREL's success and strategic initiatives. While facing challenges in pricing and reimbursement, the company is optimistic about future opportunities for growth through label expansions and market strategies.

Pacira Pharmaceuticals (PCRX) excels in Q1 2023 earnings call

Pacira Pharmaceuticals (PCRX) demonstrated robust financial performance, innovation in non-opioid pain management, and strategic market positioning in Q1 2023.
While facing challenges such as potential surgery trend moderation and pediatric market penetration, the company is leveraging opportunities in expanding EXPAREL use and regulatory advancements.
Overall, Pacira's focus on patient-centric solutions and market expansion initiatives position it well for continued growth and leadership in the pain management sector.

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.

Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion

-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- -- Company on track to submit supplemental New Drug Application in first quarter of 2023 --

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

-- European Commission decision on the Marketing Authorization Application (MAA) expected in November 2022 -- -- European Commission decision on the Marketing Authorization Application (MAA) expected in November 2022 --

Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 –

Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022

Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.

Pacira (PCRX) Up on Data From Exparel Label Expansion Study

Study achieved primary and key secondary endpoints of statistically significant reductions in postsurgical pain and opioid consumption through 96 hours Study achieved primary and key secondary endpoints of statistically significant reductions in postsurgical pain and opioid consumption through 96 hours

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Why Is Pacira (PCRX) Down 9.2% Since Last Earnings Report?

Growing since 2016 among the healthcare industry's opioid-aversion concerns, on a multi-markets basis. Institutions hold 110% of shares, insiders only 1%.

Pacira BioSciences: Pharmaceutical Near-Term Capital-Gain Prospect

-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $50.2 million for the month of July 2022. The company's net product sales include EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and the iovera° system. The company began recognizing sales of ZILRETTA in November 2021 after completing its acquisition of Flexion Therapeutics, Inc.

Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022

-- Multi-year initiative will leverage NFL Alumni events and educational opportunities to raise awareness about effective opioid alternatives -- -- Multi-year initiative will leverage NFL Alumni events and educational opportunities to raise awareness about effective opioid alternatives --

NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain

Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.

Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

Pacira Biosciences Inc. (NASDAQ:PCRX ) Q2 2022 Results Conference Call August 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, IR Dave Stack - Chairman, CEO Charlie Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Chris Neyor - JP Morgan Balaji Prasad - Barclays Gregory Renza - RBC Capital Markets Greg Fraser - Truist Securities Serge Belanger - Needham Operator Ladies and gentlemen, thank you for standing by, and welcome to the Pacira BioScience's Second Quarter 2022 Earnings Call. [Operator Instructions] I would now like to turn the call over to Susan Mesco, Head of Investor Relations.

Pacira Biosciences Inc. (PCRX) CEO Dave Stack on Q2 2022 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of -37.04% and 0.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates

-- Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition – -- Strong topline performance delivers solid net income and significantly positive adjusted EBITDA-- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2022.

Pacira BioSciences Reports Second Quarter 2022 Financial Results

TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference at 11:30 AM ET on Wednesday, August 10, 2022. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

TAMPA, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 3, 2022. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

EXPAREL average daily sales at 105% of the prior year for the second quarter and 103% of the prior year for the month of June EXPAREL average daily sales at 105% of the prior year for the second quarter and 103% of the prior year for the month of June

Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million

EXPAREL average daily sales for May 2022 were 104 percent of May 2021 EXPAREL average daily sales for May 2022 were 104 percent of May 2021

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022

Why Is Pacira (PCRX) Up 2.1% Since Last Earnings Report?

TAMPA, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference at 9:00 AM ET on Thursday, June 9, 2022 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference

More than 1,300 participants joined the recording-breaking game held at the 2022 National Senior Games Celebration of Athletes TAMPA, Fla. , May 25, 2022 /PRNewswire/ -- Pacira BioSciences, Inc. and the National Senior Games Association (NSGA) secured the new GUINNESS WORLD RECORDS title for the Largest Game of Freeze Dance.

Pacira BioSciences and the National Senior Games Association Break a GUINNESS WORLD RECORDS™ Title for the Largest Game of Freeze Dance

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive Officer Charlie Reinhart – Chief Financial Officer Conference Call Participants David Amsellem – Piper Sandler Gregory Renza – RBC Capital Markets Greg Fraser – Truist Securities Anita Dushyanth – Berenberg Capital Serge Belanger – Needham & Company Evan Hua – BMO Capital Operator Thank you for standing by, and welcome to the Q1 2022 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only mode.

Pacira BioSciences' (PCRX) CEO Dave Stack on Q1 2022 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Pacira Pharmaceuticals Stock (PCRX)